IRF2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HAP1 cell line, designed for targeted disruption of IRF2. This heterogeneous pool enables robust loss-of-function studies without clonal selection artifacts, ensuring broad representation of knockout genotypes. The polyclonal format is well-suited for transient and stable assays requiring consistent knockout effects across a population.
HAP1 is a near-haploid human cell line originating from KBM-7 chronic myeloid leukemia cells, widely used for genetic studies due to its single chromosome copy number, which simplifies knockout generation and phenotypic interpretation. The line retains functional interferon (IFN), apoptotic, and proliferative signaling pathways, providing a physiologically relevant context for studying IRF2, a central regulator of immune and cell cycle networks.
IRF2 is a transcriptional repressor that binds interferon-stimulated response elements (ISREs) to antagonize IRF1-driven activation of targets such as IFNA, IFNB1, and STAT1. Induced by IFNA/IFNB/IFNG and TLR/RIG-I/MDA5/cGAS signaling via the JAK-STAT cascade, IRF2 recruits corepressors like HDACs and interacts with EP300, RELA, and IRF9. It also influences TP53-dependent apoptosis, BAX, CDK inhibitors, and MMPs, linking innate immunity to cell cycle progression and survival.
In HAP1 cells, IRF2 knockout is expected to derepress ISRE-containing genes, elevating basal and inducible interferon responses and sensitizing cells to antiviral and antiproliferative signals. The near-haploid background ensures unambiguous genotype-phenotype correlations, while the polyclonal pool captures diverse mutation events, revealing broad functional consequences. This model offers insight into IRF2??s roles in hematopoietic malignancies, given HAP1??s myeloid origin.
Applications include ISRE-luciferase reporter assays, RT-qPCR of interferon-stimulated genes, western blotting for IRF2 and its targets (e.g., BAX, STAT1), and flow cytometric cell cycle analysis. Drug sensitivity screens, co-immunoprecipitation of IRF2 complexes, and RNA-seq transcriptome profiling are also feasible. These cells support research in antiviral signaling, cancer biology, autoimmunity, and immune-oncology. For further information, contact Ascent Research.
